Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002240316 | SCV001213338 | likely pathogenic | Ehlers-Danlos syndrome, classic type, 1 | 2024-12-17 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1489 of the COL5A1 protein (p.Gly1489Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Ehlers-Danlos syndrome (EDS) (PMID: 19370768, 22696272, 32736638). ClinVar contains an entry for this variant (Variation ID: 846084). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on COL5A1 protein function. This variant disrupts the triple helix domain of COL5A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL5A1 are more frequently observed in individuals with disease than in the general population (PMID: 22696272, 23587214). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. This variant disrupts the p.Gly1489 amino acid residue in COL5A1. Other variant(s) that disrupt this residue have been observed in individuals with COL5A1-related conditions (PMID: 10602121), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Greenwood Genetic Center Diagnostic Laboratories, |
RCV002240316 | SCV005043905 | pathogenic | Ehlers-Danlos syndrome, classic type, 1 | 2024-01-09 | criteria provided, single submitter | clinical testing | PS2, PS4_Moderate, PM1, PM2, PP2, PP3 |
| Gene |
RCV004702604 | SCV005201976 | likely pathogenic | not provided | 2024-12-05 | criteria provided, single submitter | clinical testing | Identified in individuals with classical Ehlers-Danlos syndrome (cEDS) in published literature and referred for genetic testing at GeneDx (PMID: 19370768, 22696272, 28485813); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22696272, 32736638, 28485813, 19370768) |